Evidence map›Paper›PMID 30455329›Full record

Trial reportDiabetes care2019

The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in β-Cell Function in TODAY.

Silva Arslanian, Laure El Ghormli, Joon Young Kim, Fida Bacha, Christine Chan, Heba M Ismail, Lorraine E Levitt Katz, Lynne Levitsky, Jeanie B Tryggestad, Neil H White and 1 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00081328. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00081328 phase3completed

Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial

Ran2004Enrolled699Registered outcomes11Posted comparisons0ConditionsDiabetes Mellitus, Type IIArmsLifestyle Program, Metformin, Rosiglitazone
Open the trial in the graph
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Silva ArslanianChildren's Hospital of Pittsburgh, Pittsburgh, PA.ORCID http://orcid.org/0000-0002-1528-9324
Laure El GhormliGeorge Washington University Biostatistics Center, Rockville, MD elghorml@bsc.gwu.edu.ORCID http://orcid.org/0000-0003-4223-8407
Joon Young KimChildren's Hospital of Pittsburgh, Pittsburgh, PA.ORCID http://orcid.org/0000-0003-0448-1684
Fida BachaTexas Children's Hospital, Baylor College of Medicine, Houston, TX.ORCID http://orcid.org/0000-0002-9942-1889
Christine ChanUniversity of Colorado Health Sciences Center, Denver, CO.ORCID http://orcid.org/0000-0003-3067-7672
Heba M IsmailChildren's Hospital of Pittsburgh, Pittsburgh, PA.ORCID http://orcid.org/0000-0003-0102-0030
Lorraine E Levitt KatzChildren's Hospital of Philadelphia, Philadelphia, PA.
Lynne LevitskyMassachusetts General Hospital for Children, Boston, MA.
Jeanie B TryggestadUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK.
Neil H White
TODAY Study Group
University of Oklahoma Health Sciences Center · USWashington University in St. Louis · USChildren's Hospital of Pittsburgh · USMassachusetts General Hospital · USUniversity of Colorado Health · USBaylor College of Medicine · USChildren's Hospital of Philadelphia · USGeorge Washington University · US

Funding

Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) StudyU01DK061230 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI BRAFFETT, BARBARA HALINA, ZEITLER, PHILIP S. · 2001 to 2019
$231.8M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
Washington University Institute of Clinical and Translational Sciences (UL1)UL1RR024992 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$45.4M
Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI GERALD I SHULMAN · 1993 to 2026
$44.0M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI SMITH, MATTHEW RAYMOND · 1985 to 2008
$37.4M
YOGA FOR THE MANAGEMENT OF HIV-METABOLIC SYNDROMESM01RR000036 · NCRR · WASHINGTON UNIVERSITY · PI SHAPIRO, LARRY J · 1985 to 2007
$25.4M
ZORVIRAX ORAL SUSPENSION FOR SEVERE CHILDHOOD HERPES VIRUS INFECTIONSM01RR000069 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KRUGMAN, RICHARD D. · 1985 to 2008
$22.1M
Trt. of Primary Hyperaldosteronism w/ACE Inhibitors &Angiotension Rec. BlockersM01RR014467 · NCRR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MUMFORD, MICHAEL D · 2001 to 2007
$10.4M
NCATS NIH HHS UL1 TR002345NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000069NCRR NIH HHS M01 RR000084NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR014467NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1 RR024992NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1 RR025780NIDDK NIH HHS P30 DK045735NIDDK NIH HHS T32 DK007052NIDDK NIH HHS U01 DK061212NIDDK NIH HHS U01 DK061230NIDDK NIH HHS U01 DK061239NIDDK NIH HHS U01 DK061242NIDDK NIH HHS U01 DK061254
6 · The paper itself

Abstract

objectiveObese youth without diabetes with monophasic oral glucose tolerance test (OGTT) glucose response curves have lower insulin sensitivity and impaired β-cell function compared with those with biphasic curves. The OGTT glucose response curve has not been studied in youth-onset type 2 diabetes. Here we test the hypothesis that the OGTT glucose response curve at randomization in youth in the TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study forecasts heightened glycemic failure rates and accelerated decline in β-cell function. RESEARCH DESIGN AND

methodsOGTTs (

resultsAt randomization, 21.7% had incessant increase, 68.6% monophasic, and 9.7% biphasic glucose response curves. The incessant increase group had similar insulin sensitivity but significantly lower C-peptide index and lower oDI, despite similar diabetes duration, compared with the other two groups. Glycemic failure rates were higher in the incessant increase group (58.3%) versus the monophasic group (42.3%) versus the biphasic group (39.1%) (

conclusionsIn the TODAY study cohort, an incessant increase in the OGTT glucose response curve at randomization reflects reduced β-cell function and foretells increased glycemic failure rates with accelerated deterioration in β-cell function independent of diabetes duration and treatment assignment compared with monophasic and biphasic curves. The shape of the OGTT glucose response curve could be a metabolic biomarker prognosticating the response to therapy in youth with type 2 diabetes.

Indexed as

Glucose Tolerance TestAdolescentBlood GlucoseChildC-PeptideDiabetes Mellitus, Type 2FastingFemaleHumansInsulinInsulin ResistanceInsulin-Secreting CellsLongitudinal StudiesMaleObesityBlood GlucoseC-PeptideInsulin

Identifiers

PMID30455329
PMCPMC6300703
OpenAlexW2900979192

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.